Loading
RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A receptor tyrosine kinase signalling through PI3K, MAPK and beta-catenin pathways; short isoforms act as constitutively active oncogenes.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Signalling protein present in most cells (RON receptor kinase, a secondary target of MET drugs); drugs act on the pathway rather than on a mutation that selects patients, so no prevalence applies. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"RON receptor" OR ABSTRACT:"RON receptor" OR TITLE:"MST1R" OR ABSTRACT:"MST1R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RON receptor (MST1R), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ron.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ron.json. Licence CC BY-NC 4.0.